Oakmark Select Fund CRL trades
Bill Nygren
Bill Nygren Charles River Laboratories stake
total: 60
Trades details
- Total transactions:
- 5
- New positions:
- 1
- Added:
- 4
- Held since:
- 2025 Q2
- Held for:
- 5 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Bill Nygren holds 1,498,000 Charles River Laboratories (CRL) shares with a market value of roughly $339.73M accounting for 4.09% of the overall portfolio. To date, the estimated cost basis is nearly $168.46 for "buy" trades. Oakmark Select Fund first purchased CRL in 2025 Q2, initially acquiring 678,000 shares. Since the initial investment in Charles River Laboratories (CRL), Oakmark Select Fund has made 4 more transactions.
When did Bill Nygren buy Charles River Laboratories (CRL)?
Bill Nygren first invested in Charles River Laboratories (CRL) in 2025 Q2 at the reported quarter-end price of $151.73 per share.
What's the cost basis of Oakmark Select Fund's CRL stake?
The estimated cost basis for Charles River Laboratories (CRL) stake is around $168.46 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $168.46
Bill Nygren's historical trades in Charles River Laboratories
5 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
4.09%
|
1,498,000
|
$226.79
|
$339,731,420
|
+7.15% (+100,000)
|
+0.27%
|
|
2026 Q1
|
3.19%
|
1,398,000
|
$172.50
|
$241,155,000
|
+39.24% (+394,000)
|
+0.9%
|
|
2025 Q4
|
2.45%
|
1,004,000
|
$199.48
|
$200,277,920
|
+22.14% (+182,000)
|
+0.44%
|
|
2025 Q3
|
1.71%
|
822,000
|
$156.46
|
$128,610,120
|
+21.24% (+144,000)
|
+0.3%
|
|
2025 Q2
|
1.41%
|
678,000
|
$151.73
|
$102,872,940
|
new
|
+1.41%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.